¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"pulmonary circulation time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • reaction time
    ¹ÝÀÀ½Ã°£
  • reaction time crossover
    ¹ÝÀÀ½Ã°£±³Â÷
  • real time acquisition
    ½Ç½Ã°£È¹µæ
  • real time display
    ½Ç½Ã°£Ç¥½Ã
  • real time imaging
    ½Ç½Ã°£¿µ»ó
  • real time PCR
    ½Ç½Ã°£ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ
  • real time study
    ½Ç½Ã°£°Ë»ç
  • real time ultrasonography
    ½Ç½Ã°£ÃÊÀ½ÆÄÃÔ¿µ(¼ú)
  • recirculation time
    Àç¼øÈ¯½Ã°£
  • recovery time
    ȸº¹½Ã°£
  • retention time
    Á¤Ã¼½Ã°£
  • rise time
    »ó½Â½Ã°£
  • spin lattice relaxation time
    ½ºÇɰÝÀÚÀ̿Ͻð£
  • spin-spin relaxation time
    ½ºÇɽºÇÉÀ̿Ͻð£
  • survival time
    »ýÁ¸±â°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • mean tidal time
    Æò±Õ¼øÈ¯½Ã°£
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • partial thromboplastin time
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • perception time
    Áö°¢½Ã°£, ÀνĽð£
  • person-time incidence rate
    »ç¶÷±â°£¹ß»ý·ü
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
  • polymerizing time
    ±»´Â½Ã°£, ÁßÇսð£
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • reaction time
    ¹ÝÀÀ½Ã°£
  • real time study
    ½Ç½Ã°£°Ë»ç
  • real time system
    ½Ç½Ã°£Ã¼°è
  • recirculation time
    Àç¼øÈ¯½Ã°£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • pulmonary arch
    Æóµ¿¸Æ±Ã(øËÔÑØæÏá).
  • pulmonary arch
    Æóµ¿¸Æ?øËÔÑØæÏá).
  • pulmonary area
    Æó¿µ¿ª, Æó¾ß(øËå¯).
  • pulmonary arterial pressure
    Æóµ¿¸Æ¾Ð(øËÔÑØæäâ).
  • pulmonary arteries
    Æóµ¿¸Æ(øËÔÑØæ)
  • pulmonary arteriosclerosis
    Æóµ¿¸Æ°æÈ­Áõ(øËÔÑØæÌãûùñø).
  • pulmonary arteriosclerosis
    Æóµ¿¸Æ°æÈ­Áõ(øËÔÑØæÌãûùñø)
  • pulmonary arteriovenous fistula
    Æóµ¿Á¤¸Æ·ç(øËÔÑð¡Øæ×ª).
  • pulmonary arteriovenous fistula
    Æóµ¿Á¤¸Æ·ç(øËÔÑð¡Øæ×ª)
  • pulmonary artery
    Æóµ¿¸Æ(øËÔÑØæ).
  • pulmonary artery
    ÇãÆÄµ¿¸Æ
  • pulmonary artery
    Æóµ¿¸Æ
  • pulmonary artery
    Æóµ¿¸Æ(øËÔÑØæ).
  • pulmonary artery catheter
    Æóµ¿¸ÆµµÀÚ
  • pulmonary artery pressure
    Æóµ¿¸Æ¾Ð.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • interaural time difference
    ¾çÀ̰£ µµ´Þ½Ã°£Â÷
  • intercostal real-time scanning
    ´Á°£ ½Ç½Ã°£ (ÒñÊà ãùãÁÊà) ½ºÄµ
  • intercostal real-time scanning
    ´Á°£ ½Ç½Ã°£ ½ºÄµ
  • intraretinal transit time
    ¸Á¸·³»ÀÌÇà½Ã°£
  • inversion time
    ¿ªÀü ½Ã°£
  • latent time
    Àẹ½Ã°£(íÖÜÑãÁÊà).
  • least concentration time =LCT
    ÃÖÀú³óµµ½Ã°£(¡­ãÁÊà).
  • left ventricular ejection time
    Á½ɽDZ¸Ç÷±â°£(¡­ÏÌúìÑ¢Êà).
  • longitudinal relaxation time
    Á¾Ãà ÀÌ¿Ï ½Ã°£
  • maximum phonation time
    ÃÖÀå ¹ß¼ºÁö¼Ó½Ã°£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£(̰˻Ë×Ì¡Ëà˧).
  • mean tidal time =MTT
    Æò±Õ¼øÈ¯½Ã°£(¡­âàü»ãÁÊà).
  • mixing time
    ±³¹Ý½Ã°£(ÎæÚåãÁÊà).
  • nystagmus latent time
    ¾ÈÁø(ÀÇ) Àẹ½Ã°£
  • operative time
    ¼ö¼ú½Ã°£(¼ö¼ú½Ã°£).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
V/C ventilation/circulation [ratio]
WDCC well-developed collateral circulation
PIE   1) Post-Infectious Encephalomyelitis
  2) Pulmonary Interstitial Emphysema;...
TAPVC Total Anomalous Pulmonary Venous Connection; ÀüÆóÁ¤¸Æ ¿¬°áÀÌ»ó
  = Transposition of the Pulmon...
CPE cardiac pulmonary edema; chronic pulmonary emphysema; clinical progress exercise; compensation, pens...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
PPH Persistent pulmonary hypertension
PPHN Persistent pulmonary hypertension
PPC Postoperative pulmonary complications
PPH Primary Pulmonary Hypertension
PIO-PED Prospective Investigation of Pulmonary Embolism Diagnosis
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
right superior pulmonary vein <anatomy, vein> The vein returning oxygenated blood from the superior and middle lobes of the right lung to the left atrium.
Synonym: vena pulmonalis superior dextra.
(05 Mar 2000)
chronic obstructive pulmonary disease <disease> A progressive disease process that most commonly results from smoking. Chronic obstructive pulmonary disease is characterised by difficulty breathing, wheezing and a chronic cough.
Treatment includes absolute avoidance from smoking, bronchodilators and oxygen for those with advanced disease. Complications include bronchitis, pneumonia and lung cancer.
See: emphysema.
(27 Sep 1997)
coin lesion, pulmonary Solitary, round, circumscribed shadows found in the lungs in X-ray examinations. Common causes are tuberculosis, neoplasms, cysts, or vascular anomalies.
(12 Dec 1998)
congenital absence of pulmonary valve <radiology> BIG central pulmonary arteries, big RV
(12 Dec 1998)
congenital pulmonary arteriovenous fistula Abnormal congenital communication between pulmonary arteries and veins usually found in the lung parenchyma.
(05 Mar 2000)
plexogenic pulmonary arteriopathy <syndrome> Sclerosis of the pulmonary arteries in chronic cor pulmonale; associated with severe cyanosis, it is a condition resembling polycythemia vera but resulting from primary pulmonary arteriosclerosis or primary pulmonary hypertension and characterised by plexiform lesions of arterioles.
Synonym: Ayerza's disease, cardiopathia nigra, plexogenic pulmonary arteriopathy.
(05 Mar 2000)
postcapillary pulmonary hypertension <radiology> Heart: LV failure, mitral stenosis, LA myxoma / thrombus, cor triatriatum, Pulmonary veins: congenital stenosis of pulmonary vein origin, mediastinal granulomata and neoplasms, idiopathic pulmonary veno-occlusive disease, anomalous pulmonary venous return
(12 Dec 1998)
posterior branch of right superior pulmonary vein <anatomy, vein> Drains posterior portion of superior lobe of right lung.
Synonym: ramus posterior venae pulmonalis dextrae superioris.
(05 Mar 2000)
precapillary pulmonary hypertension <radiology> Vascular: increased flow (left to right shunts), decreased flow (tetralogy of Fallot), primary pulmonary hypertension, thromboembolic disease, pulmonary arteritides, Pleuropulmonary: emphysema, diffuse lung disease, fibrothorax, chest deformity, hypoventilation, high-altitude pulmonary hypertension
(12 Dec 1998)
hantavirus pulmonary syndrome <syndrome> Acute respiratory illness in humans caused by the muerto canyon virus whose primary rodent reservoir is the deer mouse peromyscus maniculatus. First identified in the southwestern united states, this syndrome is characterised most commonly by fever, myalgias, headache, cough, and rapid respiratory failure.
(12 Dec 1998)
primary pulmonary hypertension A condition where there is increased blood pressure in the pulmonary arteries with otherwise normal heart and lungs. The cause is unknown, but there is diffuse narrowing of the pulmonary arteries resulting in increased arteriolar pressures. Secondary heart failure ensues without correction of this problem. There is an increased incidence of this disease in females between the ages of 20 and 40 years. Treatment may include a heart and lung transplant in select cases.
(27 Sep 1997)
primary pulmonary lobule The part of the airway consisting of a respiratory bronchiole and all of its branches.
Synonym: primary pulmonary lobule, respiratory lobule.
(05 Mar 2000)
sarcoidosis, pulmonary Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterised by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (cecil textbook of medicine, 19th ed, p431)
(12 Dec 1998)
high altitude pulmonary oedema <physiology> The abnormal deposition of fluid into the lungs that occurs with exposure to lower barometric pressure and low oxygen.
(12 Jan 1998)
secondary pulmonary lobule A pyramidal mass of lung tissue whose sides are bounded by the incomplete interlobular connective tissue septa and whose base, which is 1 to 2 cm in diameter, usually faces the pleural surface of the lung; lobule's that occupy a more central position in the lung are not well defined and are considered to consist of three to five pulmonary acini with proximate terminal bronchioles.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • time killer
    ½É½ÉÇ®À̰¡ µÇ´Â°Í
  • time lag
    ½Ã°£ÀÇ ¾î±ß³²;Áöü(·®)
  • time limit
    ½ÃÇÑ
  • time machine
    ŸÀӸӽŠ(°ú°Å³ª ¹Ì·¡¸¦ ¿©ÇàÇϱâ À§ÇÑ »ó»ó»óÀÇ ±â°è)
  • time note
    ¾à¼Ó¾îÀ½
  • time recorder
    ŸÀÓ ·¹ÄÚ´õ 6
  • time sharing
    (ÄÄÇ»ÅÍ) ŸÀÓ ¼Î¾î¸µ;½Ã¹èºÐ(¹æ½Ä)
  • time signal
    ½Ãº¸
  • time signature
    ¹ÚÀÚ±âÈ£
  • time sprit
    ½Ã´ëÁ¤½Å
  • triple time
    3¹ÚÀÚ
  • turnaround time
    ÃÑó¸® ½Ã°£;ȸ¼Û ½Ã°£
  • universal time
    =Greenwich Time
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á